Dawchem Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 24-06-2024
- Paid Up Capital ₹ 0.10 M
as on 24-06-2024
- Company Age 5 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.25 M
as on 24-06-2024
- Revenue 134.95%
(FY 2022)
- Profit -5.92%
(FY 2022)
- Ebitda -2.86%
(FY 2022)
- Net Worth -43.88%
(FY 2022)
- Total Assets 35.80%
(FY 2022)
About Dawchem Pharmaceuticals
The Corporate was formerly known as Dawsons Pharmaceutical Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹4.25 M.
Sanjaykumar Dawra and Jayanti Dawra serve as directors at the Company.
- CIN/LLPIN
U51397UR2018PTC009338
- Company No.
009338
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Dec 2018
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Uttarakhand
Industry
Company Details
- Location
Dehradun, Uttarakhand, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Dawchem Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjaykumar Dawra  | Director | 28-Dec-2018 | Current |
| Jayanti Dawra | Director | 28-Dec-2018 | Current |
Financial Performance of Dawchem Pharmaceuticals.
Dawchem Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 134.95% increase. The company also saw a slight decrease in profitability, with a 5.92% decrease in profit. The company's net worth observed a substantial decline by a decrease of 43.88%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dawchem Pharmaceuticals?
Unlock access to Dawchem Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Uco Bank Creation Date: 07 Dec 2021 | ₹0.36 M | Open |
Uco Bank Creation Date: 13 Jul 2020 | ₹0.64 M | Open |
Uco Bank Creation Date: 30 Nov 2019 | ₹3.25 M | Open |
How Many Employees Work at Dawchem Pharmaceuticals?
Unlock and access historical data on people associated with Dawchem Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dawchem Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dawchem Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
